Paul Edwards Posted March 20, 2016 Share Posted March 20, 2016 Cabazitaxel is a chemotherapy treatment which is used when patients become resistant to chemotherapy treatment with Docetaxel. Cabazitaxel improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Docetaxel. Androgen receptor splice variant 7 (AR-V7) in circulating tumuor cells (CTCs) from mCRPC patients was recently demonstrated to be associated with resistance to Abiraterone and Enzalutamide. A group of Dutch and Belgian researchers investigated whether this was also true for Cabazitaxel. They found that Cabazitaxel was effective even if AR-V7 was present. Reference "Efficacy of Cabazitaxel in Castration-resistant prostate cancer is independent of the presence of AR-V7 in Circulating Tumor Cells" Wendy Ostenk et alArticle Information DOI: 10.1016/j.eururo.2015.07.007 Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.